XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.21.1

Note 11 - Stockholders' Equity | 3 Months Ended
--- | ---
Mar. 31, 2021
Notes to Financial Statements |
Stockholders' Equity Note Disclosure [Text Block] | 11. Stockholders’ Equity: We have 2,000,000,000 shares of authorized common stock as of March 31, 2021 and December 31, 2020. Our common shares have rights to any dividend declared by the board of directors (the "Board"), subject to any preferential or other rights of any outstanding preferred stock, and voting rights to elect all current members of the Board. We have 80,000,000 shares of authorized preferred stock, par value $0.001 per share. The preferred shares have preferential rights over the common shares with respect to dividends and net distribution upon liquidation. We did not issue any preferred shares as of March 31, 2021. At March 31, 2021 and December 31, 2020, the adjusted closing price of our common stock was $176.69 and $207.59 per share, respectively. On February 17, 2021, our Board approved a cash dividend of $0.29 per share of common stock issued and outstanding to the holders of record as of March 15, 2021. A cash dividend of $47.1 million was paid on March 31, 2021 and recorded as a reduction to retained earnings. We paid a cash dividend of $43.9 million on March 31, 2020 at $0.27 per share of common stock issued and outstanding to the holders of record as of March 13, 2020. Share Repurchase Program Since May 2010, we have authorized repurchases of up to $4,100.0 million of our common stock through our Repurchase Program, inclusive of the $300.0 million authorization approved by our Board on February 16, 2021. Since the introduction of share repurchase as a feature of our capital management strategies in 2010, we have repurchased shares with an aggregate value of $3,621.2 million. As of March 31, 2021, we had $478.8 million available to repurchase shares through our Repurchase Program. We have no obligation to repurchase stock under this program and intend to use this authorization as a means of offsetting dilution from the issuance of shares under our 2013 Equity Incentive Plan (the "2013 Incentive Plan"), our 2009 Equity Incentive Plan (the “2009 Incentive Plan”), our sharesave plan (“UK Sharesave Plan”), and our employee stock purchase plan ("ESPP") while providing flexibility to repurchase additional shares if warranted. This authorization has no expiration date and may be increased, reduced, suspended, or terminated at any time. Shares that are repurchased under our Repurchase Program will be recorded as treasury stock and will be available for future issuance. In December 2020, we entered into an Accelerated Share Repurchase ("ASR") agreement to repurchase shares of our common stock for an aggregate purchase price of $50.0 million with HSBC Bank USA, N.A. The ASR agreement is accounted as a treasury stock transaction and forward stock purchase agreement indexed to our common stock. The forward stock purchase agreement is classified as an equity instrument under ASC 815-40, Contracts in Entity's Own Equity ("ASC 815-40") and deemed to have a fair value of zero at the respective effective date. Upon payment of the aggregate purchase price on January 4, 2021, we received an aggregate delivery of 192,687 shares of our common stock at a price of $207.59. Upon the final settlement of the ASR agreement in February 2021, we received an additional 70,787 shares as determined by the volume weighted average share price of our common stock during the term of the ASR agreement. The aggregate purchase price was recorded as a reduction to stockholders' equity in our condensed consolidated statements of changes in stockholders' equity for the three months ended March 31, 2021. These repurchases of 263,474 shares for the three months ended March 31, 2021 resulted in a reduction of outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share ("EPS"). During the three months ended March 31, 2021, we repurchased 560,526 shares of common stock with an aggregate value of $100.0 million as part of the Repurchase Program, inclusive of the ASR, at a weighted average price of $178.40 per share. We utilized cash from operations and borrowings from our Credit Facility to fund these repurchases. Treasury Stock As of March 31, 2021, our treasury stock consisted of 381,536,446 shares of common stock, carried at cost. During the three months ended March 31, 2021, we transferred 209,592 shares of common stock from the treasury shares at a weighted average treasury stock price of $11.11 per share. Earnings Per Share Basic EPS is computed by dividing net income attributable to Verisk by the weighted average number of common shares outstanding during the period. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding, using the treasury stock method, if the dilutive potential common shares, including vested and nonvested stock options, nonvested restricted stock awards, nonvested restricted stock units, nonvested performance awards consisting of performance share units (“PSU”), and nonvested deferred stock units, had been issued. The following is a presentation of the numerators and denominators of the basic and diluted EPS computations for the three months ended March 31, 2021 and 2020:
|  | Three Months Ended March 31, |
|  | 2021 |  |  | 2020 |
Numerator used in basic and diluted EPS: |  |  |  |  |  |  |  |
Net income attributable to Verisk |  | $ | 168.6 |  |  | $ | 171.7 |
Denominator: |  |  |  |  |  |  |  |
Weighted average number of common shares used in basic EPS |  |  | 162,641,819 |  |  |  | 162,894,306 |
Effect of dilutive shares: |  |  |  |  |  |  |  |
Potential common shares issuable from stock options and stock awards |  |  | 1,794,898 |  |  |  | 2,829,814 |
Weighted average number of common shares and dilutive potential common shares used in diluted EPS |  |  | 164,436,717 |  |  |  | 165,724,120 |
The potential shares of common stock that were excluded from diluted EPS were 946,563 and 1,009,520 for the three months ended March 31, 2021 and 2020, respectively, because the effect of including these potential shares was anti-dilutive. Accumulated Other Comprehensive Losses The following is a summary of accumulated other comprehensive losses as of March 31, 2021 and December 31, 2020:
|  | 2021 |  |  | 2020 |
Foreign currency translation adjustment |  | $ | (283.5 | ) |  | $ | (292.2 | )
Pension and postretirement adjustment, net of tax |  |  | (82.7 | ) |  |  | (83.5 | )
Accumulated other comprehensive losses |  | $ | (366.2 | ) |  | $ | (375.7 | )
The before tax and after tax amounts of other comprehensive income (loss) for the three months ended March 31, 2021 and 2020 are summarized below:
|  | Before Tax |  |  | Tax (Expense) Benefit |  |  | After Tax |
For the Three Months Ended March 31, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  | $ | 8.7 |  |  | $ | — |  |  | $ | 8.7 |
Pension and postretirement adjustment before reclassifications |  |  | 2.1 |  |  |  | (0.5 | ) |  |  | 1.6 |
Amortization of net actuarial loss and prior service benefit reclassified from accumulated other comprehensive losses (1) |  |  | (1.1 | ) |  |  | 0.3 |  |  |  | (0.8 | )
Pension and postretirement adjustment |  |  | 1.0 |  |  |  | (0.2 | ) |  |  | 0.8 |
Total other comprehensive income |  | $ | 9.7 |  |  | $ | (0.2 | ) |  | $ | 9.5 |
For the Three Months Ended March 31, 2020 |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  | $ | (172.6 | ) |  | $ | — |  |  | $ | (172.6 | )
Pension and postretirement adjustment before reclassifications |  |  | 2.1 |  |  |  | (0.6 | ) |  |  | 1.5 |
Amortization of net actuarial loss and prior service benefit reclassified from accumulated other comprehensive losses (1) |  |  | (1.0 | ) |  |  | 0.3 |  |  |  | (0.7 | )
Pension and postretirement adjustment |  |  | 1.1 |  |  |  | (0.3 | ) |  |  | 0.8 |
Total other comprehensive loss |  | $ | (171.5 | ) |  | $ | (0.3 | ) |  | $ | (171.8 | )
_______________
(1) | These accumulated other comprehensive loss components, before tax, are included under “Cost of revenues” and “Selling, general and administrative” in our accompanying condensed consolidated statements of operations. These components are also included in the computation of net periodic (benefit) cost (see Note 13. Pension and Postretirement Benefits for additional details).

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration